Source and scope
This summary is bounded to the recommendations, population and decisions covered by Guideline No. 393: Diabetes in Pregnancy. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC 393
Source-attributed clinical priorities
- Distinguish pre-existing diabetes from gestational diabetes and coordinate early obstetric and diabetes care for pre-existing disease.
- Use the Canadian pregnancy screening and glucose-target framework, with nutrition, monitoring and medication individualized to the pregnancy.
- Plan fetal surveillance, intrapartum glucose care and postpartum testing, including long-term type 2 diabetes prevention after gestational diabetes.
- Targets and medication plans change in pregnancy, so connect pre-existing diabetes to specialist obstetric care early.
sources for this section:SOGC 393
Practical assessment and management workflow
1
Confirm diabetes type, glucose pattern, A1C, kidney and eye status, medicines and hypoglycemia awareness.
2
Provide nutrition and glucose-monitoring education and select pregnancy-compatible therapy.
3
Coordinate fetal anatomy, growth and maternal complication surveillance.
4
Plan intrapartum glucose management, postpartum medication change and infant feeding and glucose observation.
sources for this section:SOGC 393
Safety, red flags and urgent escalation
- Diabetic ketoacidosis can occur at lower glucose levels in pregnancy and needs emergency treatment.
- Severe hypoglycemia, vomiting, ketones or reduced fetal movement requires urgent assessment.
- Stop teratogenic or insufficiently studied glucose-lowering and cardiorenal medicines under a safe replacement plan.
sources for this section:SOGC 393
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC 393
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC 393
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Society of Obstetricians and Gynaecologists of CanadaGuideline No. 393: Diabetes in Pregnancyaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.